

ISHITA DRUGS & INDUSTRIES LTD

401, 4th Floor, 3rd Eye II, Opp. Parimal Garden, Ahmedabad-380006. Ph.No.079 26468353

Date : 28th May 2016

To,
The BSE Ltd.,
Floor 25, P.J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

Dear Sirs,

Ref : Ishita Drugs & Industries Ltd (Scrip Code - 524400)


Sub : Declaration regarding unmodified audit reports in respect of standalone financial statements for the year 2015-16, under SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulation, 2016.

We hereby declare that we have submitted the audit report in respect of standalone financial statements for the financial year 2015-16, along with the financial results on 28th May 2016. We hereby confirm that the auditors have expressed an unmodified opinion in their audit reports on standalone financial statements.

Thanking You,

Your Faithfully

For, Ishita Drugs & Industries Ltd


Mr Sumit Agrawal
(CFO)





ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
Phone : +91 92280 16100 - 03 | +91 79 2646 8353 | Fax : +91 79 26404961
Regd. Office & Factory : 179/1, Vasna-Iyava, Tal. Sanand, Dist. : Ahmedabad.
E-mail : info@ishitadrugs.com | ishitadrugs@vsnl.net | URL : www.ishitadrugs.com



Date : 28th May 2016

To,
The Company Section
The Bombay Stock Exchange
Phiroz Jijibhoy Towers
Dalal Street, Bombay- 400 001

Security Code : 524400

Dear Sir,

Sub : Out come of Board Meeting held on 28th May,2016.

This is to inform you that the Board of directors of the Company at its meeting held on Monday, the 28th Day of May,2016 have approved the audited Financial Results of the Company for the quarter and year ended on 31st March, 2016.

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we enclose the following :--

- Audited Financial Results for the Quarter and year ended 31st March,2016
- Auditors Report on audited financial results
- Declaration regarding unmodified audit report.

The aforesaid is for kind information and doing the needful In the matter.

Hope the enclosed papers are in accordance with requirements.

Please acknowledge receipt.

Thanking You,

Your Faithfully

For, Ishita Drugs & Industries Ltd.

Authorised Signatory



✓ C.C. to The Company Section,
The Stock Exchange,
Kamdhenu Complex,
Panjara Pole,
Ahmedabad-380 015.

SECURITY CODE : 26940

"Our basic drugs in the service of humanity worldwide"

CIN No. L24231GJ1992PLC017054
D & B D-U-N-S Number - 65-018-0359

Ishita Drugs & Industries Ltd.

(Survey No.179/1,Village- Vasna Iyava,Taluka-Sanand,Dist-Ahmedabad-382170.)

CIN No. L24231GJ1992PLC017054

Statement of Audited Financial Results

PART I

for the quarter and year ended on 31-03-2016

(Rs. In Lacs)

	Particulars	Quarter Ended			Period Ended		Year Ended
		31-03-16 (Audited)	31-12-15 (Unaudited)	31-03-15 (Audited)	31-03-16 (Audited)	31-03-15 (Audited)	31-03-15 (Audited)
1	Income from Operation						
	(a) Net Sales/Income from operations	206.16	180.69	163.97	710.06	753.62	753.62
	(b) Other Operating income	-1.89	-0.56	-0.40	0.11	1.16	1.16
	Total Income from operations	204.27	180.13	163.57	710.17	754.78	754.78
2	Expenses						
	(a) Raw material consumption	162.20	115.95	106.95	491.92	467.07	467.07
	(b) Purchase of stock in trade	0.00	0.00	10.85	25.30	61.18	61.18
	(c) Changes in the inventories of finished	-13.65	13.91	-5.14	(12.47)	-5.09	(5.09)
	(d) Employee benefit expenses	16.04	16.95	17.44	65.06	66.27	66.27
	(e) Depreciation and amortisation expenses	3.96	3.82	5.18	15.41	15.27	15.27
	(f) Other expenses	31.56	28.07	28.13	112.87	133.19	133.19
	Total expenditure	200.11	178.70	163.41	698.10	737.89	737.89
3	Profit/loss from Operations before other income and exceptional Items (1-2)	4.16	1.43	0.17	12.07	16.89	16.89
4	Other Income	8.58	3.03	9.13	12.76	16.14	16.14
5	Profit / Loss from ordinary activities before	12.74	4.46	9.30	24.84	33.03	33.03
6	Finance cost	4.80	0.15	-0.18	5.58	4.20	4.20
7	Profit / Loss from ordinary activities before	7.94	4.31	9.48	19.26	28.83	28.83
8	Exceptional & Prior Period Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit/(Loss) from ordinary activities before tax	7.94	4.31	9.48	19.26	28.83	28.83
10	Tax expenses	2.54	0.86	2.67	5.54	6.67	6.67
11	Net Profit (+)/ Loss (-) from ordinary Activities after tax (9-10)	5.40	3.45	6.81	13.72	22.16	22.16
12	Extraordinary Items (net of tax expenses Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit (+)/ Loss (-) for the period (11-12)	5.40	3.45	6.81	13.72	22.16	22.16
14	Share of Profit/(loss) of associates						
15	Minority Interest						
16	Net Profit (+)/ Loss (-) after minority interest	5.40	3.45	6.81	13.72	22.16	22.16
17	Paid up equity share capital of Rs.10/- each	299.03	299.03	299.03	299.03	299.03	299.03
18	Reserves excluding Revaluation Reserves as per balance sheet of previous year	-	-	-	-	-	-
19	Earning Per Share (before extraordinary items)						
i	(a)Basic	0.18	0.12	0.23	0.46	0.74	0.74
	(b) Diluted						
19	Earning Per Share (after extraordinary items)						
ii	(a)Basic	0.18	0.12	0.23	0.46	0.74	0.74
	(b) Diluted						



PART II
Statement of Audited Financial Results
for the quarter and year ended on 31-03-2016

	Particulars	Quarter Ended:			Year Ended	
		31-03-16 (Audited)	31-12-15 (Unaudited)	31-03-15 (Audited)	31-03-16 (Audited)	31-03-15 (Audited)
A	PARTICULARS OF SHAREHOLDING					
1	Public Shareholding :					
	- Number of Shares (In Lacs)	15.834	15.834	15.834	15.834	15.834
	- Percentage of Share holding	52.95%	52.95%	52.95%	52.95%	52.95%
2	Promoters and promoters group Shareholding :					
	a) Pledge /Encumbered					
	- Number of Shares (In Lacs)	Nil	Nil	Nil	Nil	Nil
	- Percentage of Shares (as a % of the total share holding of promoters and promoters group	Nil	Nil	Nil	Nil	Nil
	- Percentage of Shares (as a % of the total share capital of the company	Nil	Nil	Nil	Nil	Nil
	b) Non /Encumbered					
	- Number of Shares (In Lacs)	14.069	14.069	14.069	14.069	14.069
	- Percentage of Shares (as a % of the total share holding of promoters and promoters group	100%	100%	100%	100%	100%
	- Percentage of Shares (as a % of the total share capital of the company	47.05%	47.05%	47.05%	47.05%	47.05%

Particulars	3 months ended
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	Nil
Remaining unresolved at the end of the quarter	Nil

- 1 The above results were taken on record at the Meeting of the Board of Directors held on 28.05.2016
- 2 Previous period figures have been regrouped and reclassified wherever necessary to be in conformity with the current year figures.
- 3 Provision for deferred tax, for the entire year, in accordance with the Accounting Standard AS-22, has been determined and provided in the current quarter
- 4 The figures of last quarter are the balancing figures between audited figures in respect of full financial year and the published year to date figures up to the third quarter of the current financial year.

By order of the Board

For, Ishita Drugs & Industries Ltd

Jagdish Agrawal
Director

Place : Ahmedabad
Date : 28.05.2016

Jagdish Agrawal
Director

Auditor's Report On Annual Financial Results of M/s. Ishita Drugs & Industries Ltd pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To
The Board of Directors
M/s Ishita Drugs & Industries Limited

We have audited the Statement of Annual Financial Results of M/s Ishita Drugs & Industries Ltd. for year ended 31.03.2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. This Statement has been prepared on the basis of the annual financial statements. Our responsibility is to express an opinion on these financial results based on our audit of such annual financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, as applicable, and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement (s).

An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the results. An audit also includes assessing the accounting principles used and significant estimates made by management.

We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015; and
- (ii) give a true and fair view of the net profit and other financial information for the year ended 31.03.2016.

The financial results includes the results for the Quarter ended March 31, 2016, being the balancing figure between audited figures in respect of full financial year and the published year to date figures up to the third quarter of the financial year, which were subject to limited review by us.

Date: 28/05/16
Place: Ahmedabad

For Kishor Goyal & Co.
(Chartered Accountants)
ICAI Firm Reg No. 008897N

Kishor Goyal, Partner
M. No. 047286





ISHITA DRUGS & INDUSTRIES LTD.

Corp. Off.: 401, 3rd Eye II, Opp. Parimal Garden, C. G. Road, Ahmedabad-380006.
 Phone : +91 92280 16100 / 03 | +91 79 2646 8653/7886, 2640 3214 | Fax : +91 79 2640 4961
 Regd. Office & Factory : 179/1, Vasna-Iyava, Tal.: Sanand, Dist.: Ahmedabad.
 Email : ishitadrugs@gmail.com | ishitadrugs@vsnl.net | URL : www.ishitadrugs.in

Ishita Drugs & Industries Limited

Statement of Asset & Liability for the period ended, 31.03.16

Annexure - IX

Clause 41 of the Listing Agreement For Companies (Other than Banks)

Standalone / Consolidated Statement of Assets and Liabilities		As at (current year end) (31/03/2016)	As at (previous year end) (31/03/2015)
A	Particulars		
	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	29903000	29903000
	(b) Reserves and surplus	26418294	25046517
	(c) Money received against share warrants	0	0
	Sub-total - Shareholders' funds	56321294	54949517
2	Share application money pending allotment		
3	Minority interest *	0	0
4	Non-current liabilities		
	(a) Long-term borrowings		246925
	(b) Deferred tax liabilities (net)	743915	849041
	(c) Other long-term liabilities	0	0
	(d) Long-term provisions	0	0
	Sub-total - Non-current liabilities	743915	1095966
5	Current liabilities		
	(a) Short-term borrowings	11065093	0
	(b) Trade payables	12577945	11158755
	(c) Other current liabilities	802044	804737
	(d) Short-term provisions	863557	1504447
	Sub-total - Current liabilities	25308639	13467939
	TOTAL - EQUITY AND LIABILITIES	82373848	69513422
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	11132854	12585321
	(b) Goodwill on consolidation *	0	0
	(c) Non-current investments	1536900	1536900
	(d) Deferred tax assets (net)	0	0
	(e) Long-term loans and advances	493200	493200
	(f) Other non-current assets	0	0
	Sub-total	13162954	14615421
2	Current assets		
	(a) Current investments	20001641	16653802
	(b) Inventories	7654559	13068774
	(c) Trade receivables	18808076	12549463
	(d) Cash and cash equivalents	21945498	11425102
	(e) Short-term loans and advances	787908	1052603
	(f) Other current assets	13212	148257
	Sub-total - Current assets	69210894	54898001
	TOTAL - ASSETS	82373848	69513422

"Our basic drugs in the service of humanity worldwide"

D & B D-U-N-S Number - 65-018-0359

For, Ishita Drugs & Industries Ltd

Jyoti Agrawal

Director

ISHITA DRUGS & INDUSTRIES LTD

401, 4th Floor, 3rd Eye II, Opp. Parimal Garden, Ahmedabad-380006. Ph.No.079 26468353

Date : 30th May 2016

To,
The BSE Ltd.,
Floor 25, P.J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

Dear Sirs,

Ref : Ishita Drugs & Industries Ltd (Scrip Code - 524400)


Sub : Declaration regarding unmodified audit reports in respect of standalone financial statements for the year 2015-16, under SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulation, 2016.

We hereby declare that we have submitted the audit report in respect of standalone financial statements for the financial year 2015-16, along with the financial results on 28th May 2016. We hereby confirm that the auditors have expressed an unmodified opinion in their audit reports on standalone financial statements.

Thanking You,

Your Faithfully

For, Ishita Drugs & Industries Ltd.


Mr Sumit Agrawal
(CFO)

